Exciting news was released today about the phase III studies of telaprevir combination therapy.
The top-line results released list a 75% SVR in the group that recieved 12 weeks of telaprevir/ Pegasys/ribavirin (triple combo) followed by 12 weeks of Pegasys/ribavirin (without telaprevir) vs. a 44% SVR in the group that was treated for 48 weeks with Pegasys/ribavirin (without telaprevir).
In another arm of the trial, people who recieved just 8 weeks of triple therapy followed by Pegasys/ribavirin achieved an SVR of 69%.
See Vertex's press release for more information.
We have also posted the Hepatitis Journal Review, our Weekly News Review, the Top 10 Downloads of the Month for the HBV Advocate and HCV Advocate Web sites and updated our Guide to Hepatitis B.
Join me on Twitter -
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.